Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
upreACH-2: SAR442501 in Pediatric Participants With Achondroplasia
NCT06067425Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Oct 2023
- Primary completion
- Feb 2025
- Modality
- IgG Antibodies, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 5
01
Overview
A Phase 2 trial of SAR442501 in achondroplasia (ACH), sponsored by Sanofi. Started Oct 2023; status: terminated.
02
Drugs
SAR442501
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT06067425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067425.